Latest Psoriasis Stories
Treatment for lifelong skin disease that affects nearly a million Canadians showed significant and clinically meaningful improvements in clinical studies Canadian approval comes
PETACH TIKVA, Israel, Nov. 18, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd.
Same eczema-soothing power, with a new look FORT WORTH, Texas, Nov.
- Secukinumab met primary endpoints demonstrating statistically significant improvements versus placebo in signs and symptoms of active psoriatic arthritis (PsA) in two pivotal Phase III studies
Brodalumab Meets All Primary and All Key Secondary Endpoints THOUSAND OAKS, Calif. and LONDON, Nov.
Be Joint Smart to educate roughly 48,000 local residents with PsA about their disease PORTLAND, Ore., Nov.
- Four pivotal Phase III studies of secukinumab in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) to be presented for the first time at ACR 2014 EAST HANOVER, N.J., Nov.
Drug Developers will Rely on Head-to-Head Clinical Trial Data Against Current Therapies to be Poised to Compete in the Increasingly Crowded TNF-alpha-Refractory Space BURLINGTON, Mass., Nov.
Defeat the end of Daylight Savings Time and Treat Symptoms of SAD by putting the Natural, Energizing and Productivity Boosting Benefits of Sunlight in the Palm of Your Hand. BOSTON,
New endurance program unites psoriatic disease community and cycling enthusiasts to find a cure PORTLAND, Ore., Oct.
- The parings of haberdine; also, any kind of fragments.